Vyriad launches IMMUNO-COV™, the first scalable neutralizing antibody test for COVID-19 Read More

For Healthcare Providers

The Vyriad IMMUNO-COV™ antibody test is a functional assay that specifically measures and quantifies the virus-neutralizing function of antibodies that can stop SARS-CoV-2, the virus that causes COVID-19. Other serology tests, including ELISAs and Point of Care tests like LFAs, can detect antibodies that recognize the virus but do not confirm their ability to neutralize or stop the virus from infecting new cells.

The Vyriad antibody test can only be ordered by a physician or other healthcare provider.

The IMMUNO-COV antibody test is the first commercially scalable test of its kind. The use of a genetically programmed virus to mimic SARS-CoV-2 allows the assay to be run safely in Bio Safety Level 2 CLIA-certified labs, increasing its availability. In addition, the use of a reliable luminescent readout allows for high-throughput testing.

A manuscript describing the development and validation of IMMUNO-COV™, “Development and validation of IMMUNO-COV™: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2,” is available on bioRxiv.  The website archive and distribution service accepts non-peer-reviewed articles to facilitate the rapid sharing of new scientific information about COVID-19 and other life sciences areas of research. Scientists at Vyriad and Imanis Life Sciences plan to submit this manuscript for peer review in the near future.

Vyriad developed the assay in collaboration with Imanis Life Sciences, Regeneron and Mayo Clinic.

For more information, please contact us at IMMUNO-COV@vyriad.com.